Asian Journal of Research in Pharmaceutical Sciences

K. Solanki Divya ¹, Hasumati Raj ¹, Prajapati Neelam ¹

Affiliations
1 Department of Quality Assurance, Shree Dhanvantary Pharmacy College, Kim, Dist: Surat, IN

Abstract

This review article presents the pharmacology of combined treatment of Aripiprazole and Escitalopram oxalate in treatment of Major Depressive Disorders. Aripiprazole is anti psychotic agent. Escitalopram Oxalate is also an antidepressant agent (Selective Serotonin Reuptake Inhibitor). Aripiprazole's antipsychotic activity is likely due to a combination of antagonism at D2 receptors in the mesolimbic pathway and 5HT2A receptors in the frontal cortex. Antagonism at D2 receptors relieves positive symptoms while antagonism at 5HT2A receptors relieves negative symptoms of schizophrenia. Escitalopram Oxalate is selective serotonin reuptake inhibitors (SSRIs) are a group of chemically diverse antidepressant drugs that specifically inhibit serotonin reuptake. The SSRIs block the reuptake of serotonin, leading to increased concentrations of the neurotransmitter in the synaptic cleft and, ultimately, to greater postsynaptic neuronal activity. The combination of both have decrease dose and improve Depression. Combination of both the drugs were approved by us government and has been used in Major Depressive Disorders. The main objective of this review article is to provide pharmacological information of combined therapy of of Aripiprazole and Escitalopram Oxalate to researcher in development of combined dosage form of this.

Keywords

Aripiprazole, Escitalopram Oxalate, Major Depressive Disorders, Pharmacology.

Full Text

     

Ladmeera ¹, Hasumati Raj ², Vineet Jain ²

Affiliations
1 Gujarat Technological University, Gujarat, IN
2 QualityAssurance Department, Shree Dhanvantary Pharmacy College, Kim, Surat, IN

Abstract

A simple, accurate and precise spectroscopic method was developed for simultaneous estimation of Bromhexine hydrochloride, Chlorpheniramine maleate and Guaifenesin in syrup using simultaneous equation Method. In this spectroscopic method, 249.00 nm and 261.00 nm and 274.00 nm wavelengths respectively were selected for measurement of slope and intercept according to its calibration curves. Bromhexine, Chlorpheniramine maleate and Guaifenesin show linearity in a concentration range of 02-10μg/ml, 01-05μg/ml and 25-125μg/ml at their respective λ max. Accuracy, precision and recovery studies were done by QC samples covering lower, medium and high concentrations of the linearity range. The relative standard deviation for accuracy, precision studies were found to be within the acceptance range (<2%). The limit of determination was 0.102μg/ml, 0.169μg/ml and 0.312μg/ml for Bromhexine, chlorpheniramine maleate and guaifenesin respectively. The limit of quantification was 0.311μg/ml, 0.947μg/ml and 0.514μg/ml for Bromhexine, chlorpheniramine maleate and guaifenesin respectively. Recovery of Bromhexine, guaifenesin and chlorpheniramine maleate were found to be 100.02 %, 101.17 and 100.66% respectively confirming the accuracy of the proposed method. The proposed method is recommended for routine analysis since they are rapid, simple, accurate and also sensitive and specific by no heating and no organic solvent extraction.

Keywords

Bromhexine Hydrochloride, Guaifenesin, Chlorpheniramine Maleate, Simultaneous Estimation, Simultaneous Equation Method, Analysis Method.

Full Text